The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | What is the role of autologous transplant in newly diagnosed multiple myeloma today?
In this interview, Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, discusses the role of autologous stem cell transplantation (autoSCT) in newly diagnosed multiple myeloma (MM) in the current era, highlighting the need to weigh up the benefits against the risk of side effects for eligible patients. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
